Identification of apoptosis as a target and anti-apoptotic Bcl-2 family inhibitors as effective in MCC is consistent with a prior report that demonstrated in vitro and in vivo efficacy of the Bcl-2 family inhibitor navitoclax48. This evidence concerns the gene BCL2 and Merkel cell skin cancer.